Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Everest Medicines Announces Investigational NDA Acceptance of Zetomipzomib
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 – 6, 2022 in Orlando, FL. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation that are not available in the abstract.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis (AIH).
Kezar Life Sciences Reports Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).